Bayer has announced the start of one of the largest clinical studies ever conducted to examine the benefits of using aspirin in reducing first cardiovascular and cerebrovascular disease events.
The announcement of the trial, called ARRIVE, was made at the European Society of Cardiology congress in Vienna, Austria. The study is being conducted in five countries – Germany, Italy, Spain, the UK and the USA – over a five-year period, and will look at the effects of daily low-dose aspirin in reducing the occurrence of initial fatal and non-fatal heart attacks and strokes in patients at moderate risk.
Investigators are now enrolling the first of an estimated 12,000 patients and more than 400 sites will be involved in the trial. Michael Gaziano of the Brigham and Women's Hospital in Boston, USA, the chairman of the committee overseeing the study, said: "We expect to significantly expand the existing strong body of evidence supporting use of aspirin for primary prevention of cardiovascular disease events - this time in a moderate-risk population."
Source: PharmaTimes
ps - who said the quote? Answer here.
No comments:
Post a Comment